Gut Healing Smart Pill

More than 3 million Americans live with inflammatory bowel disease (IBD), a painful, lifelong condition that causes patients to suffer from chronic diarrhea, abdominal pain, bleeding, and a dramatically reduced quality of life. IBD is usually treated with a class of drugs called biologics, which calm the immune system to reduce inflammation and cost $60,000 to $100,000 per patient per year. When drugs fail, surgery often becomes the only option. Up to 80% of people with Crohn’s disease eventually require surgical removal of damaged intestine, at a cost of $30,000 to $60,000 per procedure, with many patients needing more than one operation over their lifetime. The root cause of this cycle is that biologics reduce inflammation but do not directly help the gut lining rebuild itself. This failure to achieve full restoration of the intestinal lining is the key driver of relapse, resulting in patient hospitalizations, escalating drug costs, and worsening long-term outcomes. Together, these preventable consequences account for a large share of the $14 billion annual cost of IBD care in the U.S.

The team brings a unique approach to treat IBD by activating the gut's own built-in repair system. The researchers have found that a protein called E-cadherin acts like a biological on/off switch for intestinal stem cell activity. When E-cadherin is briefly reduced in the intestinal epithelium, stem cells wake up, multiply, and rapidly rebuild the damaged lining. The challenge is delivering the right treatment to exactly the right location within the intestine to avoid off-target effects on healthy areas, which are long, winding, and very difficult to access from the outside. The team will address this challenge by building a smart swallowable capsule, about the size of a large vitamin, that can sense damaged sections of the gut as it travels through the intestine, using a technology called bioimpedance, which measures the electrical properties of the gut wall, and deliver healing therapy to the areas that need it. The therapy will be delivered in two steps. First, the capsule deposits tiny nanoparticles onto the damaged gut lining, and these particles carry a short genetic signal into the cells to switch on the repair process. Second, the team’s approach will complement the biologic drugs that patients are already being treated with. By repairing the gut lining as inflammation is reduced, patients will respond better to their current medications, switch drugs less often, and ultimately require fewer surgeries.

This innovative technology ultimately seeks to improve the quality of life for millions of IBD patients and reduce the multi-billion-dollar cost of repeated hospitalizations and surgeries. The team will establish a cross-campus research hub, training a new cohort of students in regenerative medicine and bioengineering, and will produce scientific evidence demonstrating that gut-healing therapy is real, safe, and ready to move toward human testing. Once the platform is established, the same capsule-and-nanoparticle system can be loaded with other therapeutic agents, such as anti-inflammatory drugs, growth factors, or gene therapies, making it a flexible delivery tool that can be used for additional health applications, in addition to E-cadherin and IBD.